Semaglutide biosimilar is under clinical development by Leto Laboratories and currently in Phase II for Diabetes.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

More than two billion people worldwide live with overweight or obesity, conditions closely linked to an array of health ...

Claiming Science magazine's breakthrough of the year in 2023 , these drugs are an absolute revelation: they give you ...

Discover the inspiring weight loss journey of a dietitian who overcame PCOS and pregnancy challenges to achieve lasting ...